Attovia Therapeutics, Inc. (ATTO) Stock Analysis & Investment Frameworks
Attovia Therapeutics, Inc. (ATTO) stock analysis on Invetso. Review Attovia Therapeutics, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Attovia Therapeutics, Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Attovia Therapeutics, Inc. Key Financial Metrics
- Market Cap: $647.33M
- Revenue: $1.35M
- ROE: -32.05%
- ROIC: -35.46%
- Dividend Yield: N/A
About Attovia Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.